瑞替普酶在急性心肌梗死溶栓治疗中的应用效果分析

Reteplase Thrombolytic Therapy in AMI Application Effect Analysis

目的:探讨瑞替普酶(reteplase,rPA)在急性心肌梗死(AMI)溶栓治疗中的的临床疗效及安全性。方法:将60例发病6小时内的符合溶栓治疗条件的AMI患者分为两组,其中rPA组和尿激酶(Urokinase,UA)组各30例,分别用rPA和UA进行溶栓,比较两组患者在溶栓治疗后的再通率,各种并发症的发生率。结果:溶栓后rPA组再通率均明显高于尿激酶组(P<0.05);溶栓后死亡及内心力衰竭、心源性休克和再梗死的发生率等并发症rPA组明显低于尿激酶组(P<0.05);溶栓后出血的发生率两组差异无统计学意义(P>0.05)。结论:rPA溶栓治疗AMI是安全有效的。

Objective：To explore the efficacy and safety of reteplase for the treatment of acute myocardial infarction（AMI）.Methods：60 patients were randomly divided into treatment group（30 cases）and control group（30 cases）,treatment group was treated with rPA intravenous thrombolytic thempy and the control group was treated with Urokinase,and then observed thrombolytic recanalization rate and complication rate of two groups of patients.Results：The recanalization rate of rPA group was significantly higher than that of UA group after thrombolysis（P＆lt;0.05）;The death rate and congestive heart failure,cardiogenic shock and reinfarction incidence complications afte thrombolysis in rPA group was significantly lower than the UA group afte thrombolysis（P＆lt;0.05）;the incidence of hemorrhage after thrombolysis in two groups have no significant difference（P＆gt;0.05）.Conclusion：Thrombolytic therapy of Rpa for AMI is safe and effective.